A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.

Interventions: Patients receive aflibercept (4 mg/kg) every 2 weeks on day 1 of each cycle followed immediately by FOLFIRI. Treatment continues until disease progression, unacceptable toxicity, death, patient refusal, or investigator decision. Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose